Nigrostriatal dopaminergic vulnerability in Parkinson’s disease: Neuroprotective strategies
Open Access
- 13 August 2025
- journal article
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (8) , 3378-3386
Abstract
The selective vulnerability of nigrostriatal dopaminergic neurons is a hallmark of Parkinson’s disease and underlies its progressive motor decline. These neurons are uniquely susceptible to degeneration due to their extensive axonal arborization, high energy demands, sustained pacemaking activity, and cytosolic dopamine metabolism, which collectively promote oxidative stress and mitochondrial dysfunction. Advances in single-nucleus RNA sequencing and spatial transcriptomics have revealed transcriptionally distinct dopaminergic subtypes within the human substantia nigra pars compacta, such as AGTR1 + /SOX6 + and RIT2 + populations, which exhibit subtype-specific transcriptional stress signatures and are preferentially lost in Parkinson’s disease. These findings underscore the role of intrinsic vulnerability, influenced by genetic risk loci, mitochondrial stress, and protein misfolding pathways, including α-synuclein aggregation. Furthermore, neuroinflammation, iron accumulation, and vascular dysfunction act synergistically to amplify neuronal loss. This review integrates molecular, cellular, and systems-level mechanisms contributing to dopaminergic degeneration and evaluates emerging neuroprotective strategies. These include anti-oxidative, anti-inflammatory, mitochondrial therapies, novel biomarkers, gene editing, and cell replacement techniques. Understanding the selective vulnerability of nigrostriatal subtypes offers a promising path toward precision-targeted, disease-modifying treatments for Parkinson’s disease.Keywords
This publication has 123 references indexed in Scilit:
- Ethics and regulation of neuronal optogenetics in the European UnionPflügers Archiv - European Journal of Physiology, 2023
- Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?Journal of Neural Transmission, 2023
- Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patientsAlzheimer's & Dementia, 2022
- StimFit—A Data‐Driven Algorithm for Automated Deep Brain Stimulation ProgrammingMovement Disorders, 2021
- Parkinson's disease: Is it a consequence of human brain evolution?Movement Disorders, 2019
- Neuronal vulnerability, pathogenesis, and Parkinson's diseaseMovement Disorders, 2012
- A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouseBrain Structure and Function, 2011
- Molecular mechanisms underlying levodopa-induced dyskinesiaMovement Disorders, 2008
- Preventing and controlling dyskinesia in Parkinson's disease-A view of current knowledge and future opportunitiesMovement Disorders, 2008
- Morphological taxonomy of the neurons of the primate striatumJournal of Comparative Neurology, 1991